Memphis Pharmaceuticals results, Q2 2024
Net profit, assets, equity and cash flow for Q2 2024, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit58.12 millionEGP · +290.2% vs the same period a year earlier
Total assets1 billionEGP · +71.1% vs the same period a year earlier
Shareholders' equity148 millionEGP · +153.0% vs the same period a year earlier
Operating cash flow96.49 millionEGP · +2884.7% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Q2 2024 was about 58.12 million EGP, up +290.2% from 14.9 million EGP in Q2 2023.
- Total assets at the end of Q2 2024 were about 1 billion EGP, and shareholders' equity about 148 million EGP.
- Operating cash flow for Q2 2024 was positive at 96.49 million EGP.
Key lines against the same period a year earlier
This periodQ2 2023Change
Net profit58.12 million14.9 million+290.2%
Gross profit103 million55.79 million+84.8%
Total assets1 billion587 million+71.1%
Total liabilities856 million528 million+62.1%
Shareholders' equity148 million58.56 million+153.0%
Total liabilities and equity1 billion587 million+71.1%
Operating cash flow96.49 million-3.47 million+2884.7%
Investing cash flow8.86 million-991 thousand+994.2%
Financing cash flow133 million2.34 million+5583.7%
Net change in cash238 million-2.11 million+11372.8%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy